Development of a 3-day manufacturing method to generate CD19-CD20-CD22 trispecific CAR T-cells from whole blood
Authors:
Open Access
- 15 July 2026
- journal article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Abstract
Background: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for many hematological malignancies. However, high relapse rates and limited accessibility remain significant challenges. We developed a 3-day streamlined process to address these limitations. Methods: T-cells were isolated from whole blood collected from healthy donors via an automated density gradient separation that included a T-isopure™ antibody cocktail, which isolates T-cells through negative selection. T-cells were activated then transduced with a lentiviral vector encoding a trispecific CAR. T-cells were cultured in G-Rex vessels and harvested at day 3 or day 7 for analysis. CAR expression and T-cell phenotype were assessed by flow cytometry and gene expression analysis. Functional activity was evaluated by measuring cytotoxicity and cytokine secretion following co-culture with target cell lines. Results: The T-isopure isolation enriched CD3 + T-cells in whole blood from 18.9% to 88.5% of CD45 + cells, with a mean recovery of 40.6%. RBCs were depleted with ≥ 99% efficiency, with monocytes and NK cells comprising the bulk of remaining CD45 + cells. The 3-day manufacturing process produced T-cells with > 95% viability, 53% transduction efficiency, and vector copy number < 3 copies/cell. Phenotypic analysis revealed a high proportion of stem/central memory T-cells at both timepoints, with no significant differences observed. Cytotoxicity assays demonstrated strong and sustained killing of NALM6 tumor cells, comparable between both products. Gene expression profiling indicated that day 3 products were less differentiated, exhibiting a memory-like phenotype and reduced inflammatory signaling, further supported by protein analysis of culture supernatants. Conclusion: This study establishes a rapid, GMP-compliant method for manufacturing polyfunctional, CAR T-cells directly from whole blood. The workflow outlined here achieved a potent, phenotypically favorable CAR T-cell product without compromising viability or cytotoxic function. Compared to the standard 7-day method, the 3-day approach resulted in expression of genes associated with a more stem-like phenotype while reducing manufacturing time and cost. This method may provide a practical alternative for decentralized CAR T-cell manufacturing, particularly in resource-limited settings.Keywords
Funding Information
- National Institutes of Health (Z99CL999999)
This publication has 44 references indexed in Scilit:
- OAS cross-activates RNase L intercellularly through cell-to-cell transfer of 2-5A to spread innate immunityImmunity, 2025
- Genetic retargeting of E3 ligases to enhance CAR T cell therapyCell Chemical Biology, 2023
- L-Selectin expression is associated with inflammatory microenvironment and favourable prognosis in breast cancer3 Biotech, 2021
- Total Costs of Chimeric Antigen Receptor T-Cell ImmunotherapyJAMA Oncology, 2018
- Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen SensitivityImmunity, 2018
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive GlioblastomaJAMA Oncology, 2017
- Parsing the Interferon Transcriptional Network and Its Disease AssociationsCell, 2016
- IL‐2 and IL‐15 regulate CD8+ memory T‐cell differentiation but are dispensable for protective recall responsesEuropean Journal of Immunology, 2015
- Interferon-stimulated genes and their antiviral effector functionsCurrent Opinion in Virology, 2011
- Regulated expression of the inhibitory receptor LAIR‐1 on human peripheral T cells during T cell activation and differentiationEuropean Journal of Immunology, 2007